I-MOVE+ (Integrated Monitoring of Vaccines in Europe)

I-MOVE+ (Integrated Monitoring of Vaccines in Europe) is a consortium of 24 partners (regional and national public health Institutes, SME, Universities frrom of 17 European Union / European Economic Area Member States.

Its goal is to develop a sustainable platform of primary care, hospital and laboratory networks that use  validated  standardised  methods  to  evaluate existing  and  new  vaccines programmes independently from commercial interests.

I-MOVE+ has received a major grant (May 2015- Oct 2018) from the European Commission (H2020) Horizon 2020 program to identify, pilot test, use, and disseminate the best study designs to measure, in near real time the effectiveness and impact of vaccines used in the elderly population to prevent influenza and pneumococcal infections.

I-MOVE+ project’s Work package 3 (WP3): Pneumococcal vaccines is led jointly by National Institute of Health and Welfare (THL), Finland and EpiConcept, France. Work Package leader is Professor Pekka Nuorti, THL and Faculty of Social sciences, Tampere University, Finland.
 

The  primary  objective  of  work  package  3  (WP3)  is  to  estimate  the  effectiveness  (direct  effect)  and  impact  (overall and indirect effect) of available pneumococcal vaccines against invasive pneumococcal disease (IPD),  community-acquired pneumonia (CAP) and potentially against other respiratory diseases in adults 65 years and  older. This will be accomplished by using and enhancing the available surveillance  systems and existing data sources in the participating countries.

WP3 leaders: National Institute for Health and Welfare (THL) & EpiConcept